Author: Mike Woods

Awareness, Public Health, Safety
No Comments

Falls in Older Adults

As I approach 70 years old, I find myself being more careful going down stairs and reaching out more often to catch my balance. Although I have not had a significant fall — unless I count when I’m mountain biking — I still worry about it like most older adults. More than 25% of adults aged 65 years or older fall each year, with one out of five falls resulting in a serious injury such as fractures of the hip, wrist, humerus, and pelvis, head and brain injury, chronic disabilities, and even death (36,000 in 2020). The risk increases with […]

Read More
COVID-19, Prescription Drugs
No Comments

COVID-19 Treatments No Longer Covered by the Government

In a blog posted here on May 16, 2023 I discussed the phasing out of the January 2020 Federal Government COVID-19 public health emergency. At that time The Food and Drug Administration (FDA) continued to authorize the COVID-19 antiviral drug nirmatrelvir/ritonavir (Paxlovid) for emergency use. It has since been fully approved for adults with Covid at high risk of hospitalization or death, such as older adults and those with medical conditions like diabetes, asthma, and obesity. The government continued to provide Paxlovid at no cost to patients until November 1, 2023. Insurance companies will now be able to charge for […]

Read More
Health, Public Health, Vaccinations
No Comments

Respiratory Syncytial Virus

As a pediatrician I am very familiar with respiratory syncytial virus (RSV). In infants and young children RSV infection results in a sometimes frightening seasonal illness called bronchiolitis. The virus affects the smallest airways, called the bronchioles, and results in wheezing and trouble breathing. There is no effective antiviral medication, only supportive treatment. The illness is especially severe in premature infants. In June 1998 one of the first monoclonal antibody drugs palivizumab was approved as a preventative measure given to premature infants at high risk for severe infection. In July 2023 another monoclonal antibody drug named nirsevimab-alip was approved for […]

Read More
BeMedWise, Health, Prescription Drugs, Specialty Drugs
No Comments

New Alzheimer’s Drugs Proven to Work

Alzheimer’s disease is a neurological disease that is the most common cause of dementia. It causes progressive destructive and irreversible changes in the brain. A common feature is the accumulation of a protein called amyloid-β in the form of plaques and tau tangles. Both are thought to cause brain cell death. Although among the most likely candidates, they have not yet been shown to be the cause of Alzheimer’s disease. In a blog from 2 years ago a newly approved drug for Alzheimer’s disease named aducanumab was discussed. At the time I thought the medication had not been proven to […]

Read More
Affordable Care Act
No Comments

Science vs Politics Part II: The Preventive Care Mandate

Mifepristone: Science vs Politics discussed the ruling of a Federal District Judge in Texas on Alliance for Hippocratic Medicine v. FDA that banned the use of mifepristone for abortions. After many challenges, including the current administration, this ruling was mitigated by the 5th U.S. Circuit Court of Appeals which provided a compromise ruling that allowed the use of mifepristone, but only until seven weeks after conception; down from the previous ten weeks limit. This ruling only affected a small number of people.   A different conservative Federal District Judge in Texas has now made a ruling on Braidwood Management v. […]

Read More
1 2 3 … 5

About Us

Welcome to the NeedyMeds Voice! We look forward to presenting you with timely, provocative pieces on healthcare reform, patient advocacy, medication and healthcare access, and other health-related news. Our goals are to educate, enlighten, and elucidate; together, we will try to make sense of the myriad and ongoing healthcare-related changes in the U.S. today.